Motley Fool7d agoneutral
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of ItGenerate Biomedicines focuses on AI-enabled drug discovery.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
308last 24h
2125last 7d
378● bullish (7d)
185● bearish (7d)
204publishers
The Wall Street Journal13d agoneutral
Jersey Mike’s Is the Latest Stock Slide in Trading Debuts This YearJersey Mike’s Subs, with its 5.96% stock-price decline Thursday, is hardly alone in having a first-day share slide. This year, shares for hedge fund Pershing Square, nuclear fuel company Standard Nuclear and biotech firm Generate Biomedicines fell 18%, 18% and 21% respectively on their first trading days, according to Dealogic.
Motley Fool36d agoneutral
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on MondayArk Invest's top investor is adding to stocks that went public over the past year.
Insider Monkey50d agoneutral
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 14, Morgan Stanley increased its price objective on Generate Biomedicines, Inc. (NASDAQ:GENB) to $22 from $20. The firm maintained an “Overweight” rating on the shares. Separately, Generate Biomedicines, Inc. (NASDAQ:GENB)’s GB-0895 (anti-TSLP) program […]
Simply Wall St.72d agoneutral
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent GainsRecent trading snapshot and business context Generate Biomedicines (GENB) has drawn investor interest after a mixed stretch in the stock, with a small gain of 0.2% over the past day set against a decline of 9.7% over the past week. Over the past month the stock is roughly flat, while the past 3 months show a gain of 10.0%. This recent trading context sits alongside a market value of about US$1.68b and a share price of US$13.12 at the last close. See our latest analysis for Generate...
Motley Fool73d agoneutral
A New $21 Million Position Signals Confidence in This Post-IPO Drug DeveloperThis biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
Barchart84d agoneutral
This AI Biotech Stock Landed a $10.4 Million Nvidia InvestmentNvidia’s backing highlights growing confidence in AI-powered biotech stocks.
Simply Wall St.158d agoneutral
Generate Biomedicines (GENB) Valuation Check After Recent Share Price WeaknessGenerate Biomedicines: Recent Trading Moves And Core Business Snapshot Generate Biomedicines (GENB) has seen recent share price pressure, with a 10% decline over the past week and a similar move over the past month, bringing the latest close to US$11.21. For context, the company reports revenue of US$31.893 million alongside a net loss of US$249.523 million, reflecting the costs of developing its generative biology platform and early stage pipeline of protein based therapeutics. See our...
MT Newswires166d agoneutral
Sector Update: Health Care Stocks Advance Late AfternoonHealth care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S